3-149846069-G-A
Variant summary
Our verdict is Benign. Variant got -9 ACMG points: 0P and 9B. BP4_StrongBP6BS2
The ENST00000392894.8(RNF13):c.43G>A(p.Val15Ile) variant causes a missense change. The variant allele was found at a frequency of 0.00000683 in 1,611,512 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a benign outcome for this variant. 13/21 in silico tools predict a benign outcome for this variant. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. V15D) has been classified as Uncertain significance.
Frequency
Consequence
ENST00000392894.8 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Benign. Variant got -9 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
RNF13 | NM_183381.3 | c.43G>A | p.Val15Ile | missense_variant | 2/10 | ENST00000392894.8 | NP_899237.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
RNF13 | ENST00000392894.8 | c.43G>A | p.Val15Ile | missense_variant | 2/10 | 1 | NM_183381.3 | ENSP00000376628 | P1 |
Frequencies
GnomAD3 genomes AF: 0.0000397 AC: 6AN: 151164Hom.: 0 Cov.: 32
GnomAD3 exomes AF: 0.0000119 AC: 3AN: 251162Hom.: 0 AF XY: 0.00000737 AC XY: 1AN XY: 135736
GnomAD4 exome AF: 0.00000342 AC: 5AN: 1460348Hom.: 0 Cov.: 30 AF XY: 0.00000275 AC XY: 2AN XY: 726496
GnomAD4 genome AF: 0.0000397 AC: 6AN: 151164Hom.: 0 Cov.: 32 AF XY: 0.0000542 AC XY: 4AN XY: 73792
ClinVar
Submissions by phenotype
not specified Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Ambry Genetics | Apr 06, 2024 | The c.43G>A (p.V15I) alteration is located in exon 3 (coding exon 1) of the RNF13 gene. This alteration results from a G to A substitution at nucleotide position 43, causing the valine (V) at amino acid position 15 to be replaced by an isoleucine (I). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. - |
not provided Benign:1
Benign, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Nov 27, 2023 | - - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at